Literature DB >> 8096110

Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the fucose-mannose ligand (FML).

C B Palatnik-de-Sousa1, H S Dutra, R Borojevic.   

Abstract

Leishmania donovani promastigote glycoconjugate ligands, studied in our laboratory, that interact with the internalization receptors on BALB/c macrophages: the 'fucose mannose ligand' (FML), the 'phosphate mannogalactan ligand' (PMGL), and the 'lipopeptidephosphoglycan' (LPPD), interfered also with interaction between amastigotes and host cells in vitro. Among the three compounds studied, the FML was shown to be the most potent inhibitor of both promastigote and amastigote internalization, and to be present on parasite surface during the vertebrate-host cycle. The FML, but not the other two glycoconjugates, is a potent immunogen in rabbits (ELISA, agglutination and immuno-blots). Rabbit hyperimmune sera recognized essentially the 36 kDa band of FML. Mouse monoclonal antibodies against FML recognized either the 36 kDa or the 55 kDa band. No cross-reactivity between these two FML components was detected. No antigenic similarity could be detected between the 36 and 55 kDa bands of FML and the 'GP63' (promastigote surface proteinase) major surface leishmanial antigen. The 36 kDa-glycoprotein was identified as the major FML antigenic fraction and designated 'GP36'. The integrity of the glycidic moiety was necessary for its antigenicity. This L. donovani surface glycoprotein is apparently one of the major molecules involved in interactions between the parasite and the vertebrate host.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096110     DOI: 10.1016/0001-706x(93)90006-w

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  12 in total

Review 1.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

2.  The efficacy of L. (L.) chagasi excreted-secreted antigens (ESAs) for visceral leishmaniasis diagnosis is due to low levels of cross-reactivity.

Authors:  Viviana Pinedo-Cancino; Norival Kesper; Clara Lúcia Barbiéri; José Angelo Lauletta Lindoso; Eufrosina Setsu Umezawa
Journal:  Am J Trop Med Hyg       Date:  2013-01-16       Impact factor: 2.345

3.  Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response.

Authors:  Dirlei Nico; Carla Claser; Gulnara P Borja-Cabrera; Luiz R Travassos; Marcos Palatnik; Irene da Silva Soares; Mauricio Martins Rodrigues; Clarisa B Palatnik-de-Sousa
Journal:  PLoS Negl Trop Dis       Date:  2010-11-09

4.  Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties.

Authors:  Elissa M Hudspeth; Qian Wang; Christopher A Seid; Molly Hammond; Junfei Wei; Zhuyun Liu; Bin Zhan; Jeroen Pollet; Michael J Heffernan; C Patrick McAtee; David A Engler; Risë K Matsunami; Ulrich Strych; Oluwatoyin A Asojo; Peter J Hotez; Maria Elena Bottazzi
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

5.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

Review 6.  Nucleoside Hydrolase NH 36: A Vital Enzyme for the Leishmania Genus in the Development of T-Cell Epitope Cross-Protective Vaccines.

Authors:  Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2019-04-16       Impact factor: 7.561

7.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30

8.  Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains.

Authors:  Dirlei Nico; Daniele Crespo Gomes; Marcus Vinícius Alves-Silva; Elisangela Oliveira Freitas; Alexandre Morrot; Diana Bahia; Marcos Palatnik; Mauricio M Rodrigues; Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2014-05-01       Impact factor: 7.561

9.  NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis.

Authors:  Dirlei Nico; Fernanda Martins Almeida; Juliana Maria Motta; Fellipe Soares Dos Santos Cardoso; Celio Geraldo Freire-de-Lima; Leonardo Freire-de-Lima; Paula Melo de Luca; Ana Maria Blanco Martinez; Alexandre Morrot; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2018-05-07       Impact factor: 7.561

10.  Cytokine profile and nitric oxide levels in peritoneal macrophages of BALB/c mice exposed to the fucose-mannose ligand of Leishmania infantum combined with glycyrrhizin.

Authors:  Hasan Namdar Ahmadabad; Reza Shafiei; Gholam Reza Hatam; Reza Zolfaghari Emameh; Ashok Aspatwar
Journal:  Parasit Vectors       Date:  2020-07-20       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.